A trial looking at INC424 for myelofibrosis

This is a trial to learn more about a drug called INC424 for myelofibrosis.

Myelofibrosis (pronounced my-eh-lo-fy-bro-sis) is a rare blood disorder that causes scarring of the bone marrow. A small number of people with myelofibrosis go on to develop acute myeloid leukaemia.

Myelofibrosis can develop without having had any other condition. This is called primary myelofibrosis (PMF) or chronic idiopathic myelofibrosis. It can also develop in people who have polycythaemia vera or thrombocythaemia. This is called secondary myelofibrosis. This trial is for people with either primary or secondary myelofibrosis.

We know from earlier trials that a type of biological therapy called INC424 can help people with myelofibrosis. But researchers want to learn more about how well it works and how it affects peoples’ quality of life.

The aims of the trial are to

• See how 2 different doses of INC424 help people with myelofibrosis

• Learn more about the side effects